Alkem Laboratories completes acquisition of Adroit Biomed

Alkem Laboratories (BSE: ALKEM) announced today the completion of its acquisition of Adroit Biomed Limited, effective April 23, 2025. This follows earlier intimations on February 7, 2025, and March 28, 2025, regarding the intended acquisition, where the Stock Exchanges were informed of the acquisition by the Company, of 100% stake of Adroit Biomed Limited (“Adroit”), a company incorporated in India. As a result of the completed transaction, Adroit Biomed now operates as a wholly owned subsidiary of Alkem Laboratories. The acquisition was completed in accordance with the terms and conditions outlined in the share purchase agreement dated March 28, 2025. Alkem Laboratories will make the disclosure available on the company website.